Puerarin 6''-O-Xyloside
Based on 1 Customer Validation
Puerarin 6''-O-Xyloside is one of the major iso-flavones found in P. lobata. Puerarin 6''-O-Xyloside inhibits cancer cells proliferation, induces apoptosis by upregulating cleaved caspase-3, 7, 9, Bax and downregulating Bcl-2 levles and inhibits tumor growth in mice. Puerarin 6''-O-Xyloside has anti-osteoporotic activity in ovariectomized mice. Puerarin 6''-O-Xyloside inhibits mushroom tyrosinase with an IC50 of 513.8 μM. Puerarin 6''-O-Xyloside can be used for the research of human lung carcinoma, osteoporosis, melanosis and melanomar.
For research use only. We do not sell to patients.
- Purity: 99.81%
- CAS No.: 114240-18-5
- Formula: C26H28O13
- Molecular Weight:548.49
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Apoptosis Compound Library
HY-L003
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Glycoside Compound Library
HY-L042
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Pyroptosis Compound Library
HY-L059
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Flavonoids Library
HY-L068
-
Mitochondria-Targeted Compound Library
HY-L089
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Mitophagy Compound Library
HY-L180
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
All Caspase Isoforms
More
Biological Activity
|
Caspase-3 |
Caspase-7 |
Caspase-9 |
Bax |
Bcl-2 |
Puerarin 6''-O-Xyloside (10-40 μM; 32 h) potently inhibits the proliferation of human lung carcinoma A549 cells in a concentration-dependent manner[1].
Puerarin 6''-O-Xyloside (10-40 μM; 32 h) induces apoptosis in human lung carcinoma A549 cells in a concentration-dependent manner[1].
Puerarin 6''-O-Xyloside (10-40 μM; 32 h) promotes the release of cytochrome c from mitochondria to the cytoplasm in human lung carcinoma A549 cells in vitro in a concentration-dependent manner[1].
Puerarin 6''-O-Xyloside (10-40 μM; 32 h) modulates apoptosis-related protein expression in human lung carcinoma A549 cells, significantly upregulating cleaved caspase-3, cleaved caspase-7, cleaved caspase-9, and Bax, while downregulating Bcl-2 in a concentration-dependent manner[1].
Puerarin 6''-O-Xyloside (5-20 μM; 24-72 h) significantly enhances the proliferation of primary osteoblasts isolated from calvarias of 3-day-old newborn SD rats in a dose-dependent manner[2].
Puerarin 6''-O-Xyloside (5-20 μM; 48 h) significantly decreases RANKL expression, increases OPG expression, and up-regulates the OPG/RANKL ratio in primary osteoblasts isolated from calvarias of 3-day-old newborn SD rats[2].
Puerarin 6''-O-Xyloside (100-1600 μM; 20 min) exhibits dose-dependent inhibitory activity against mushroom tyrosinase with an IC50 of 513.8 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human lung carcinoma A549 cells
-
Concentration:10 μM; 20 μM; 40 μM
-
Incubation Time:32 h
-
Result:Reduced cell viability in a concentration-dependent manner.
-
Cell Line:human lung carcinoma A549 cells
-
Concentration:10 μM; 20 μM; 40 μM
-
Incubation Time:32 h
-
Result:Induced apoptosis in A549 cells in a concentration-dependent manner.
Increased the percentage of total apoptotic cells (early + late) progressively with rising concentrations.
Observed the highest apoptosis rate at 40 μM.
-
Cell Line:human lung carcinoma A549 cells
-
Concentration:10 μM; 20 μM; 40 μM
-
Incubation Time:32 h
-
Result:Increased cytoplasmic cytochrome c levels in a concentration-dependent manner.
Decreased mitochondrial cytochrome c levels in a concentration-dependent manner.
Upregulated cleaved caspase-3, caspase-7, caspase-9 protein levels in a concentration-dependent manner.
Upregulated Bax protein levels in a concentration-dependent manner and downregulated Bcl-2 protein levels in a concentration-dependent manner.
Puerarin 6''-O-Xyloside (20-60 mg/kg; i.p.; after 12 weeks of OVX operation) exerts significant dose-dependent anti-osteoporotic activity in ovariectomized mice, as evidenced by reduced body weight, increased uterine index, elevated serum Ca2+, phosphorus, ALP, and OPG levels, and improved bone histology[2].
Puerarin 6''-O-Xyloside (10-80 mg/kg; i.p.; single dose) shows no acute toxicity in healthy female ICR mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice were injected in the right flank subcutane-
ously with A549 cells[1] -
Dosage:40 mg/kg
-
Administration:i.p.
-
Result:Significantly suppressed A549 tumour growth during a 15 d observation period.
Showed no significant difference in body weight relative to control mice.
-
Animal Model:ICR (female, 3-month-old, bilateral ovariectomy-induced)[2]
-
Dosage:20 mg/kg; 40 mg/kg; 60 mg/kg
-
Administration:i.p.; daily; 12 weeks
-
Result:Decreased body weights of ovariectomized mice relative to untreated controls at 40 and 60 mg/kg.
Increased uterine index in a dose-dependent manner compared to untreated controls.
Increased serum blood calcium, phosphorus, alkaline phosphatase (ALP), osteoprotegerin (OPG) levels in a dose-dependent manner relative to untreated controls.
Improved osteoporotic bone changes (thickened compact bone, thicker/more compact trabecular bone) at all tested doses; yielded nearly normal femur tissue morphology at 60 mg/kg.
Chemical Information
-
CAS No. 114240-18-5
-
Appearance Solid
-
Molecular Weight 548.49
-
Formula C26H28O13
-
Color White to off-white
-
SMILES
OC1=CC=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=C1[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO[C@H](OC[C@@H](O)[C@@H]5O)[C@@H]5O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 100 mg/mL (182.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chen T, et al. In vitro and in vivo antitumour activities of puerarin 6″-O-xyloside on human lung carcinoma A549 cell line via the induction of the mitochondria-mediated apoptosis pathway. Pharm Biol. 2016;54(9):1793-1799. [Content Brief]
[2]. Li H, et al. Anti-osteoporotic activity of puerarin 6"-O-xyloside on ovariectomized mice and its potential mechanism. Pharm Biol. 2016;54(1):111-117. [Content Brief]
[3]. Zhao CP, et al. Adsorbed hollow fiber immobilized tyrosinase for the screening of enzyme inhibitors from Pueraria lobata extract. J Pharm Biomed Anal. 2021;193:113743. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8232 mL | 9.1159 mL | 18.2319 mL | 45.5797 mL |
| 5 mM | 0.3646 mL | 1.8232 mL | 3.6464 mL | 9.1159 mL | |
| 10 mM | 0.1823 mL | 0.9116 mL | 1.8232 mL | 4.5580 mL | |
| 15 mM | 0.1215 mL | 0.6077 mL | 1.2155 mL | 3.0386 mL | |
| 20 mM | 0.0912 mL | 0.4558 mL | 0.9116 mL | 2.2790 mL | |
| 25 mM | 0.0729 mL | 0.3646 mL | 0.7293 mL | 1.8232 mL | |
| 30 mM | 0.0608 mL | 0.3039 mL | 0.6077 mL | 1.5193 mL | |
| 40 mM | 0.0456 mL | 0.2279 mL | 0.4558 mL | 1.1395 mL | |
| 50 mM | 0.0365 mL | 0.1823 mL | 0.3646 mL | 0.9116 mL | |
| 60 mM | 0.0304 mL | 0.1519 mL | 0.3039 mL | 0.7597 mL | |
| 80 mM | 0.0228 mL | 0.1139 mL | 0.2279 mL | 0.5697 mL | |
| 100 mM | 0.0182 mL | 0.0912 mL | 0.1823 mL | 0.4558 mL |
Puerarin 6''-O-Xyloside Related Classifications
HY-N2135 Related Classifications
Powered by Bioz